Newborn Screening definition
Newborn Screening or "newborn screening tests" means screening infants for the disorders of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium- chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders. Severe Combined Immunodeficiency (SCID) spinal muscular atrophy (SMA), x- linked adrenoleukodystrophy (X-ALD), mucopolysaccharidosis type I (MPS I) and Pompe disease upon completion of laboratory validation studies, establishment of short-term follow-up services, and approval by the Commissioner of Health.
Newborn Screening or "newborn screening tests" means screening infants for the disorders of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), and after October 1, 2007, upon completion of validation studies and establishment of short-term follow-up services, biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, and organic acid disorders, and upon completion of laboratory validation studies and establishment of short-term follow-up services, Severe Combined Immunodeficiency (SCID) detectable via the Department's laboratory technology utilized in newborn screening and approved by the Commissioner of Health and critical congenital heart
Newborn Screening or "newborn screening tests" means screening infants for the disorders of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium- chain acyl conenzyme A dehydrogenase deficiency (MCAD), biottinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders. Severe Combined Immunodeficiency (SCID) spinal muscular atrophy (SMA), x- linked adrenoleukodystrophy (X-ALD), mucopolysaccharidoisis type I (MPS I) and pompe disease upon completion of laboratory validation studies, establishment of short-term follow-up services, and approval by the Commissioner of Health. Also includes critical congenital heart disease (CCHD) via pulse oximetry screening conducted by birthing facilities on all newborns born in the state of Oklahoma.
Examples of Newborn Screening in a sentence
Under Grant Number U22MC24078 (CFDA# 93.110) (the “Cooperative Agreement”) from the Health Resources and Services Administration (“HRSA”) of the U.S. Department of Health and Human Services (“HHS”), APHL administers the Newborn Screening Technical assistance and Evaluation Program (“NewSTEPs”).
APHL will share the data identified on Exhibit F from each state with the Newborn Screening Clearinghouse, the Newborn Screening Translational Research Network and the National Coordinating Center for the Regional Genetic Service Collaborative each a federally funded NBS program.
Medical foods are covered within limitations defined in the AMPM for members diagnosed with a metabolic condition included under the ADHS Newborn Screening Program and specified in the AMPM.
It provides a Comprehensive Newborn Screening System to track patients with test results outside normal limits and ensure screening tests' accuracy.
At the 11th European regional meeting of the International Society of Newborn Screening (ISNS) in Bratislava, Slovakia (October 2018), a session about newborn screening for SCID was organized in which experiences of several countries with regard to SCID screening were shared.
More Definitions of Newborn Screening
Newborn Screening or "newborn screening tests" means screening infants for the disorders of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, and upon completion of laboratory validation studies and establishment of short-term follow-up services, Severe Combined Immunodeficiency (SCID) spinal muscular atrophy (SMA), x-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidoisis type I (MPS I) and pompe disease upon completion of laboratory validation studies, and establishment of short-term follow-up services, detectable via the Department's laboratory technology utilized in newborn screening and approvedal by the Commissioner of Health. and cAlso includes Critical congenital heart disease (CCHD) via pulse oximetry screening conducted by birthing facilities on all newborns born in the state of Oklahoma.
Newborn Screening means the use of various laboratory and clinical tests to screen infants for certain inherited disorders where a potential net benefit and availability of effective treatments have been demonstrated.
Newborn Screening or "newborn screening tests" means the use of various laboratory and clinical tests to screening screen infants for the certain inherited disorders where a potential net benefit and availability of effective treatments have been demonstrated. of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, Severe Combined Immunodeficiency
Newborn Screening means the testing of infants to identify those at increased risk for
Newborn Screening or "testing" means the testing of a blood sample for classical phenylketonuria (PKU) and certain other amino acid, organic acid, and fatty acid oxidation disorders, primary hypothyroidism, classical galactosemia, congenital adrenal hyperplasia due to 21-hydroxylase deficiency, biotinidase deficiency, sickle cell disease/trait, cystic fibrosis, and lysosomal storage disorders, and severe combined immunodeficiency. At times, variant forms of some disorders, or related conditions, may also be identified.
Newborn Screening or "newborn screening tests" means the use of various laboratory and clinical tests to screening screen infants for the certain inherited disorders where a potential net benefit and availability of effective treatments have been demonstrated. of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, Severe Combined Immunodeficiency (SCID) spinal muscular atrophy (SMA), x-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidoisis type I (MPS I) and pompe disease upon completion of laboratory validation studies, establishment of short-term follow-up services, and approval by the Commissioner of Health.
Newborn Screening means the DBS testing of infants.